港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

拨康视云-B

4.330

-0.130-2.91%

成交量：23.40万

成交额：101.80万

市值：36.59亿

市盈率：-2.67

高：4.450

开：4.450

低：4.300

收：4.460

52周最高：9.740

52周最低：3.940

股本：8.45亿

香港流通股本：8.45亿

量比：0.97

换手率：0.03%

股息：- -

股息率：- -

每股收益(LYR):-1.621

净资产收益率：--

总资产收益率：-44.38%

市净率：-1.43

市盈率(LYR):-2.67

市销率: 45.96

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

拨康视云-B

交易所：

SEHK

成立时间：

2015

员工人数：

60

公司地址：

8921 Research Drive,Irvine,California,United States

官网：

http://cloudbreakpharma.com

邮编：

92618

电话：

- -

传真：

- -

简介：

Cloudbreak Pharma Inc是一家临床阶段的眼科生物技术公司，从事开发各种治疗方法。该公司专注于眼科疗法的内部发现、开发和商业化。该公司拥有两款核心产品 CBT-001和CBT-009，均为自主研发。该公司的核心产品CBT-001用于治疗翼状胬肉（一种良性增生性眼表疾病），已在美国和中国启动III期多区域临床试验（MRCT）。该公司的核心产品CBT-009用于治疗青少年近视（5至19岁儿童和青少年的近视），已完成I/II期临床试验。该公司的其他候选药物处于相对早期的开发阶段，包括另外两种临床阶段候选药物，即CBT-006和CBT-004，以及四种临床前阶段候选药物，即CBT-007、CBT-199、CBT-145和CBT-011。

董事

名称

职位

NI Jinsong

董事会主席，执行董事

Van Son DINH

执行董事

YANG Rong

执行董事

赖显荣

独立非执行董事，薪酬委员会委员，提名委员会主席，审核委员会委员

聂四江

独立非执行董事，薪酬委员会主席，提名委员会委员，审核委员会委员

马遥豪

独立非执行董事，薪酬委员会委员，提名委员会委员，审核委员会主席

LI Jun Zhi

非执行董事，薪酬委员会委员，提名委员会委员，审核委员会委员

曹旭

非执行董事

夏志东

非执行董事

股东

名称

职位

NI Jinsong

首席执行官

冯雅芳

财务总监，公司秘书

Elizabeth Sharon CAPAN

首席合规官，首席专利官

Van Son DINH

首席营运官

YANG Rong

首席科学官

Abu P ABRAHAM

首席医疗官

FANG Wenkui Ken

首席创新官

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02592/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02592","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","market":"HK","secType":"STK","nameCN":"拨康视云-B","latestPrice":4.33,"timestamp":1763366895008,"preClose":4.46,"halted":0,"volume":234000,"delay":0,"floatShares":844999999,"shares":844999999,"eps":-1.6209587773916962,"marketStatus":"已收盘","change":-0.13,"latestTime":"11-17 16:08:15","open":4.45,"high":4.45,"low":4.3,"amount":1017990,"amplitude":0.033632,"askPrice":4.4,"askSize":1000,"bidPrice":4.33,"bidSize":13500,"shortable":3,"etf":0,"ttmEps":-1.3093289180134169,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":5,"adr":0,"listingDate":1751472000000,"exchange":"SEHK","adjPreClose":4.46,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"volumeRatio":0.965347,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","floatShares":844999999,"roa":"-44.38%","roe":"--","lyrEps":-1.620959,"volumeRatio":0.965347,"shares":844999999,"dividePrice":0,"high":4.45,"amplitude":0.033632,"preClose":4.46,"low":4.3,"week52Low":3.94,"pbRate":"-1.43","psRate":"45.96","week52High":9.74,"institutionHeld":0,"latestPrice":4.33,"committee":0.862069,"eps":-1.6209587773916962,"divideRate":0,"volume":234000,"delay":0,"ttmEps":-1.3093289180134169,"open":4.45,"prevYearClose":10.1,"prevWeekClose":4.46,"prevMonthClose":4.71,"prevQuarterClose":4.51,"fiveDayClose":4.7,"twentyDayClose":4.78,"sixtyDayClose":5.27},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02592\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"02592","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02592\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02592\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02592\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02592","date":"2025-11-14","current":-3.307012,"percent":0.365591,"low":-13.478827,"twenty":-12.207573,"median":-6.465107,"eighty":-5.621104,"high":-5.348116,"avg":-8.53714,"sd":3.119566,"marketCap":3741462218},"quantilePoints":[{"date":"2025-07-04","current":-6.317277,"twenty":-6.610502,"median":-6.500542,"eighty":-6.390583,"marketCap":4915912241},{"date":"2025-07-11","current":-6.166376,"twenty":-6.470405,"median":-6.317277,"eighty":-6.263403,"marketCap":4798467239},{"date":"2025-07-18","current":-6.350904,"twenty":-6.498689,"median":-6.350281,"eighty":-6.263403,"marketCap":4941079027},{"date":"2025-07-25","current":-6.080141,"twenty":-6.48004,"median":-6.306537,"eighty":-6.134066,"marketCap":4731355809},{"date":"2025-08-01","current":-5.497985,"twenty":-6.418895,"median":-6.177156,"eighty":-6.011186,"marketCap":4278353657},{"date":"2025-08-08","current":-5.49809,"twenty":-6.350655,"median":-6.13405,"eighty":-5.65539,"marketCap":4278353657},{"date":"2025-08-15","current":-5.725306,"twenty":-6.343182,"median":-6.058573,"eighty":-5.554248,"marketCap":4446132232},{"date":"2025-08-22","current":-5.53457,"twenty":-6.315129,"median":-6.004685,"eighty":-5.554248,"marketCap":4286742586},{"date":"2025-08-29","current":-5.503941,"twenty":-6.295753,"median":-5.870846,"eighty":-5.538055,"marketCap":4253186871},{"date":"2025-09-05","current":-5.413205,"twenty":-6.239682,"median":-5.742284,"eighty":-5.49926,"marketCap":4186075441},{"date":"2025-09-12","current":-12.640894,"twenty":-6.350655,"median":-5.870846,"eighty":-5.508123,"marketCap":4118964011},{"date":"2025-09-19","current":-12.711577,"twenty":-6.612702,"median":-6.004685,"eighty":-5.525012,"marketCap":4135741868},{"date":"2025-09-26","current":-11.804503,"twenty":-12.358821,"median":-6.058573,"eighty":-5.527436,"marketCap":3842129362},{"date":"2025-10-03","current":-6.439136,"twenty":-12.191113,"median":-6.134046,"eighty":-5.53457,"marketCap":2096453591},{"date":"2025-10-10","current":-5.988337,"twenty":-11.881825,"median":-6.134089,"eighty":-5.548508,"marketCap":1949083838},{"date":"2025-10-17","current":-12.3346,"twenty":-12.21981,"median":-6.187936,"eighty":-5.561014,"marketCap":4009907937},{"date":"2025-10-24","current":-11.844495,"twenty":-12.25273,"median":-6.279578,"eighty":-5.580054,"marketCap":3850518291},{"date":"2025-10-31","current":-12.15705,"twenty":-12.335851,"median":-6.333467,"eighty":-5.585568,"marketCap":3951185436},{"date":"2025-11-07","current":-11.838569,"twenty":-12.273198,"median":-6.424535,"eighty":-5.601607,"marketCap":3850518291},{"date":"2025-11-14","current":-11.510378,"twenty":-12.207573,"median":-6.465107,"eighty":-5.621104,"marketCap":3741462218}],"updateTime":1763377323318},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1934212103,"yearFounded":2015,"employeeNum":60,"address":"8921 Research Drive,Irvine,California,United States","zipCode":"92618"},"stockCompanyDetail":{"websiteUrl":"http://cloudbreakpharma.com","stockEarnings":[{"period":"1week","weight":-0.0283},{"period":"1month","weight":-0.0388},{"period":"3month","weight":-0.1585},{"period":"6month","weight":-0.5584},{"period":"ytd","weight":-0.5584}],"compareEarnings":[{"period":"1week","weight":0.0126},{"period":"1month","weight":0.0255},{"period":"3month","weight":0.0515},{"period":"6month","weight":0.1382},{"period":"1year","weight":0.3672},{"period":"ytd","weight":0.3247}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"Cloudbreak Pharma Inc是一家临床阶段的眼科生物技术公司，从事开发各种治疗方法。该公司专注于眼科疗法的内部发现、开发和商业化。该公司拥有两款核心产品 CBT-001和CBT-009，均为自主研发。该公司的核心产品CBT-001用于治疗翼状胬肉（一种良性增生性眼表疾病），已在美国和中国启动III期多区域临床试验（MRCT）。该公司的核心产品CBT-009用于治疗青少年近视（5至19岁儿童和青少年的近视），已完成I/II期临床试验。该公司的其他候选药物处于相对早期的开发阶段，包括另外两种临床阶段候选药物，即CBT-006和CBT-004，以及四种临床前阶段候选药物，即CBT-007、CBT-199、CBT-145和CBT-011。","exchange":"SEHK","name":"拨康视云-B","nameEN":"CLOUDBREAK-B"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"02592\",market:\"HK\",,,undefined,":{"directors":[{"name":"NI Jinsong","position":"董事会主席，执行董事"},{"name":"Van Son DINH","position":"执行董事"},{"name":"YANG Rong","position":"执行董事"},{"name":"赖显荣","position":"独立非执行董事，薪酬委员会委员，提名委员会主席，审核委员会委员"},{"name":"聂四江","position":"独立非执行董事，薪酬委员会主席，提名委员会委员，审核委员会委员"},{"name":"马遥豪","position":"独立非执行董事，薪酬委员会委员，提名委员会委员，审核委员会主席"},{"name":"LI Jun Zhi","position":"非执行董事，薪酬委员会委员，提名委员会委员，审核委员会委员"},{"name":"曹旭","position":"非执行董事"},{"name":"夏志东","position":"非执行董事"}],"executives":[{"name":"NI Jinsong","position":"首席执行官"},{"name":"冯雅芳","position":"财务总监，公司秘书"},{"name":"Elizabeth Sharon CAPAN","position":"首席合规官，首席专利官"},{"name":"Van Son DINH","position":"首席营运官"},{"name":"YANG Rong","position":"首席科学官"},{"name":"Abu P ABRAHAM","position":"首席医疗官"},{"name":"FANG Wenkui Ken","position":"首席创新官"}]}}}